How can MSI enhance our understanding of ASO distribution?

被引：0

作者：

van der Vloet, Laura ^{[1
]}

Hilaire, Pierre Barbier Saint ^{[2
]}

Bouillod, Christophe ^{[2
]}

Isin, Emre M. ^{[2
]}

Heeren, Ron M. A. ^{[1
]}

Vandenbosch, Michiel ^{[1
]}

机构：

[1] Maastricht Univ, Maastricht MultiModal Mol Imaging Inst M4I, Div Imaging Mass Spectrometry IMS, Univ Singel 50, NL-6229 ER Maastricht, Netherlands

[2] Inst Rech & Dev Servier Paris Saclay, Rue Francis Perrin, F-91190 Gif Sur Yvette, France

来源：

DRUG DISCOVERY TODAY | 2025年 / 30卷 / 01期

关键词：

antisense oligonucleotide; ADMET; mass spectrometry imaging; spatial omics; multimodal imaging; IONIZATION MASS-SPECTROMETRY; ANTISENSE OLIGONUCLEOTIDES; NUCLEIC-ACIDS; BRAIN; TISSUE; DRUGS; MECHANISMS; MOUSE; NEUROTRANSMITTERS; BIODISTRIBUTION;

D O I：

10.1016/j.drudis.2024.104275

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In the dynamic field of drug discovery and development, a comprehensive understanding of drug absorption, distribution, metabolism, excretion, and toxicity is crucial. Mass spectrometry imaging (MSI) has become a key analytical tool in the pharmaceutical industry, allowing evaluation of drug biodistribution and molecular profiles. Antisense oligonucleotides (ASOs) are emerging drug candidates for treating neurologic diseases. This review explores the potential of MSI in investigating ASOs' spatial distribution within neurological disease models. Here, we focus on multimodal molecular imaging to gain insights into ASO distribution, simultaneously with a better understanding of the molecular pathways affected by ASOs. An improved understanding of therapeutic ASOs in tissue will potentially improve neurologic therapies, emphasizing their importance in patient care.

引用

页数：16

共 96 条

[91] Desorption electrospray ionization mass spectrometry: Imaging drugs and metabolites in tissues [J].